Compare TGL & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | ABP |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.5M |
| IPO Year | 2022 | N/A |
| Metric | TGL | ABP |
|---|---|---|
| Price | $4.88 | $1.91 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 399.5K | 31.2K |
| Earning Date | 02-13-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,305,713.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $4.51 | $1.94 |
| 52 Week High | $289.90 | $36.00 |
| Indicator | TGL | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 26.48 |
| Support Level | $5.16 | $2.00 |
| Resistance Level | $5.69 | $2.90 |
| Average True Range (ATR) | 0.39 | 0.40 |
| MACD | -0.21 | -0.13 |
| Stochastic Oscillator | 5.11 | 7.35 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.